Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis

BACKGROUND: The efficacy of CD22 or CD19 chimeric antigen receptor T (CAR‐T) cells in the management of acute lymphoblastic leukemia (ALL) and non‐Hodgkin lymphoma (NHL) was observed. Because antigen loss and lack of CAR‐T‐cell persistence are the leading causes of progressive disease following sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Thuy, Thanh Nhu, Nguyen, Chen, Chia‐Ling, Lin, Chiou‐Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557829/
https://www.ncbi.nlm.nih.gov/pubmed/37667978
http://dx.doi.org/10.1002/cam4.6497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557829/
https://www.ncbi.nlm.nih.gov/pubmed/37667978
http://dx.doi.org/10.1002/cam4.6497

Ejemplares similares